مقاله‌های دارای تعهدات انتشار عمومی - James L. Gulleyبیشتر بدانید
جای دیگری دردسترس نیست: ۷
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
JL Gulley, PM Arlen, KY Tsang, J Yokokawa, C Palena, DJ Poole, ...
Clinical Cancer Research 14 (10), 3060-3069, 2008
تعهدات: US National Institutes of Health
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
AB Apolo, R Nadal, Y Tomita, NN Davarpanah, LM Cordes, SM Steinberg, ...
The Lancet Oncology 21 (8), 1099-1109, 2020
تعهدات: US National Institutes of Health
IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL: MP15-10
T Sanford, R Donahue, C Jochems, R Dolan, S Bellfield, M Anderson, ...
Journal of Urology 197 (4), e174, 2017
تعهدات: US National Institutes of Health
483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with …
C Floudas, J Strauss, C Allen, R Donahue, C Jochems, S Steinberg, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A513-A513, 2021
تعهدات: US National Institutes of Health
MP67-16 SURGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT VACCINE THERAPY (PROSTVAC) PRIOR TO RADICAL PROSTATECTOMY: A PHASE II EXPERIENCE
Z Blake, D Nemirovsky, A Kenigsberg, N Mendhiratta, J Enders, ...
Journal of Urology 209 (Supplement 4), e949, 2023
تعهدات: US National Institutes of Health
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
YT Tsai, R Donahue, N Toney, J Strauss, J Gulley, J Schlom
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A6-A6, 2021
تعهدات: US National Institutes of Health
New frontiers in therapy for metastatic prostate cancer
JL Gulley
Drug Discovery Today: Therapeutic Strategies 7 (1-2), 1-3, 2010
تعهدات: US National Institutes of Health
جای دیگری دردسترس است: ۲۶۴
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ...
Journal of Clinical Oncology 28 (7), 1099-1105, 2010
تعهدات: US National Institutes of Health
Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study
AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ...
Journal of Clinical Oncology 35 (19), 2117-2124, 2017
تعهدات: US National Institutes of Health
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ...
The Lancet Oncology 19 (1), 51-64, 2018
تعهدات: US National Institutes of Health
Antibody-dependent cellular cytotoxicity activity of a novel anti–PD-L1 antibody avelumab (MSB0010718C) on human tumor cells
B Boyerinas, C Jochems, M Fantini, CR Heery, JL Gulley, KY Tsang, ...
Cancer immunology research 3 (10), 1148-1157, 2015
تعهدات: US National Institutes of Health
Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial
ML Disis, MH Taylor, K Kelly, JT Beck, M Gordon, KM Moore, MR Patel, ...
JAMA oncology 5 (3), 393-401, 2019
تعهدات: US National Institutes of Health
Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors
J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ...
Clinical Cancer Research 24 (6), 1287-1295, 2018
تعهدات: US National Institutes of Health
Current landscape of immunotherapy in breast cancer: a review
S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ...
JAMA oncology 5 (8), 1205-1214, 2019
تعهدات: US National Institutes of Health
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
RA Madan, M Mohebtash, PM Arlen, M Vergati, M Rauckhorst, ...
The lancet oncology 13 (5), 501-508, 2012
تعهدات: US National Institutes of Health
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ...
Cancer Immunology, Immunotherapy 59, 663-674, 2010
تعهدات: US National Institutes of Health
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label …
JL Gulley, A Rajan, DR Spigel, N Iannotti, J Chandler, DJL Wong, J Leach, ...
The Lancet Oncology 18 (5), 599-610, 2017
تعهدات: US National Institutes of Health
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ...
The Lancet Oncology 18 (5), 587-598, 2017
تعهدات: US National Institutes of Health
The role of lineage plasticity in prostate cancer therapy resistance
H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ...
Clinical cancer research 25 (23), 6916-6924, 2019
تعهدات: US National Institutes of Health
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
WD Stein, JL Gulley, J Schlom, RA Madan, W Dahut, WD Figg, Y Ning, ...
Clinical Cancer Research 17 (4), 907-917, 2011
تعهدات: US National Institutes of Health
اطلاعات انتشارات و تأمین بودجه به‌طورخودکار توسط برنامه رایانه‌ای تعیین می‌شود.